Lentiviral Vector Envelope Segmentation for T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for generating engineered T-cell products require complex engineering of viral envelope proteins to display mitogenic antibodies and cytokines, leading to reduced viral titre and increased costs due to the use of single-use consumables.
Innovation Solution
Incorporating mitogenic and cytokine-based transmembrane proteins into the retroviral or lentiviral capsid, separate from the viral envelope glycoprotein, to activate and transduce T-cells, thereby simplifying the process and maintaining viral titre.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral envelope protein is engineered to display mitogenic antibodies and cytokines, then T-cell activation is achieved, but viral titre is reduced
Solution Approach 1:
The invention divides the activation function from the viral envelope structure by using separate transmembrane proteins (such as CD3ζ, CD28, OX40L, 4-1BBL) that are incorporated into the viral particle independently of the envelope glycoprotein. This segmentation allows the envelope to maintain its structural integrity and viral titre while the separate activation proteins provide T-cell stimulation without compromising viral replication capacity.
2Reliability
If complex engineering of viral envelope protein is performed, then mitogenic stimulation is achieved, but device complexity increases
Solution Approach 1:
The invention extracts the mitogenic stimulation function from the viral envelope protein by using separate, pre-engineered transmembrane proteins that can be independently expressed and incorporated into the viral particle. This extraction simplifies the overall system design as the envelope protein does not need to be complexly engineered to display multiple functions, reducing both manufacturing complexity and the risk of compromising viral titre.
3Reliability
If single-use consumables (mitogen antibodies and cytokines) are used, then T-cell activation is achieved, but costs increase
Solution Approach 1:
The invention enables the viral vector system to provide its own activation function through the incorporation of transmembrane proteins into the viral particle. This self-service capability eliminates the need for separate mitogen antibodies and cytokine consumables, as the viral particle itself delivers the activation signals directly to T-cells during infection, thereby reducing material costs and streamlining the production process.
Data Source
AI summary
The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and/or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and/or the cytokine-based T-cell activating transmembrane protein.